BSD, ProZyme partner to redefine biotherapeutic glycan analysis workflow

BioSystem Development, LLC (BSD) and ProZyme, Inc. announce a partnership to redefine biotherapeutic glycan analysis workflow. The first product from this collaboration combines ProZyme's proprietary enzymatic N-deglycosylation, labeling and cleanup chemistry with BSD's AssayMAP™ high- throughput micro chromatography platform resulting in a rapid, quantitative N-glycan sample preparation method fully enabled for any scale of automation.

“We're pleased to combine our AssayMAP technology with ProZyme chemistry and expertise, and we look forward to introducing reliable, high-throughput solutions to help advance biotherapeutic research and development”

Therapeutic proteins are typically glycosylated during biosynthesis, which can critically affect their clinical efficacy and pharmacokinetics. Conventional glycan analysis methods are laborious and expensive taking up to 3 or more days to perform. The GlykoScreen™ Rapid Glycosylation Sample Preparation System (RGSPS) processes hundreds of samples in 3 hours or less using common laboratory equipment. The 96-well SBS-standard format is designed for both manual liquid handling and automated workstations. The system includes an optional integrated purification module for antibody samples. N-glycan sample preparation is the first in a family of glycan analysis applications being developed on the same platform. Product demonstrations are underway at major biopharmaceutical companies.

"We're pleased to combine our AssayMAP technology with ProZyme chemistry and expertise, and we look forward to introducing reliable, high-throughput solutions to help advance biotherapeutic research and development," said Scott Fulton, founder and CEO of BioSystem Development. Jo Wegstein, President of ProZyme agreed: "We believe that the products of this partnership will have a profound impact on advancing the field of glycobiology and look forward to leading this initiative."